Switch theme
Sign up to access all valuation multiples
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
2021
65
LTM Revenue $46.7M
LTM EBITDA -$67.0M
$329M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
2seventy bio has a last 12-month revenue of $46.7M and a last 12-month EBITDA of -$67.0M.
In the most recent fiscal year, 2seventy bio achieved revenue of $37.9M and an EBITDA of -$98.4M.
2seventy bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 2seventy bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $100M | $37.9M | XXX | XXX | XXX |
| Gross Profit | $65.3M | $83.5M | XXX | XXX | XXX |
| Gross Margin | 65% | 220% | XXX | XXX | XXX |
| EBITDA | -$206M | -$98.4M | XXX | XXX | XXX |
| EBITDA Margin | -206% | -260% | XXX | XXX | XXX |
| Net Profit | -$254M | -$218M | XXX | XXX | XXX |
| Net Margin | -253% | -575% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, 2seventy bio's stock price is $5.
2seventy bio has current market cap of $260M, and EV of $329M.
See 2seventy bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $329M | $260M | XXX | XXX | XXX | XXX | $-0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, 2seventy bio has market cap of $260M and EV of $329M.
2seventy bio's trades at 7.0x LTM EV/Revenue multiple, and -4.9x LTM EBITDA.
Analysts estimate 2seventy bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for 2seventy bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $329M | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | -3.3x | XXX | XXX | XXX |
| P/E | -4.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign Up2seventy bio's NTM/LTM revenue growth is 51%
2seventy bio's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.9M for the same period.
Over next 12 months, 2seventy bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate 2seventy bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for 2seventy bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -62% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -260% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -52% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -209% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 203% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 319% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
2seventy bio acquired XXX companies to date.
Last acquisition by 2seventy bio was XXXXXXXX, XXXXX XXXXX XXXXXX . 2seventy bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was 2seventy bio founded? | 2seventy bio was founded in 2021. |
| Where is 2seventy bio headquartered? | 2seventy bio is headquartered in United States of America. |
| How many employees does 2seventy bio have? | As of today, 2seventy bio has 65 employees. |
| Who is the CEO of 2seventy bio? | 2seventy bio's CEO is Mr. William D. Baird, III. |
| Is 2seventy bio publicy listed? | Yes, 2seventy bio is a public company listed on NAS. |
| What is the stock symbol of 2seventy bio? | 2seventy bio trades under TSVT ticker. |
| When did 2seventy bio go public? | 2seventy bio went public in 2021. |
| Who are competitors of 2seventy bio? | Similar companies to 2seventy bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of 2seventy bio? | 2seventy bio's current market cap is $260M |
| What is the current revenue of 2seventy bio? | 2seventy bio's last 12-month revenue is $46.7M. |
| What is the current EBITDA of 2seventy bio? | 2seventy bio's last 12-month EBITDA is -$67.0M. |
| What is the current EV/Revenue multiple of 2seventy bio? | Current revenue multiple of 2seventy bio is 7.0x. |
| What is the current EV/EBITDA multiple of 2seventy bio? | Current EBITDA multiple of 2seventy bio is -4.9x. |
| What is the current revenue growth of 2seventy bio? | 2seventy bio revenue growth between 2023 and 2024 was -62%. |
| Is 2seventy bio profitable? | Yes, 2seventy bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
